Rituximab is associated with late onset neutropenia (LON) when administered with doxorubicin-based chemotherapy for the initial treatment of aggressive B-cell lymphomas.

被引：0
|
作者：
Dunleavy, KM
Little, RF
Grant, N
White, T
Wright, G
Janik, J
Wilson, WH
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1443
引用
收藏
页码：397A / 398A
页数：2
相关论文
共 17 条
  • [1] Rituximab plus CHOP for the treatment of Sjogrens syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis, M
    Giannouli, S
    Anagnostou, D
    Tzioufas, AG
    Tzioufas, AG
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S575 - S575
  • [2] Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma
    Arai, Yasuyuki
    Yamashita, Kouhei
    Mizugishi, Kiyomi
    Nishikori, Momoko
    Hishizawa, Masakatsu
    Kondo, Tadakazu
    Kitano, Toshiyuki
    Kawabata, Hiroshi
    Kadowaki, Norimitsu
    Takaori-Kondo, Akifumi
    Hematology, 2015, 20 (04) : 196 - 202
  • [3] Rituximab may overcome bcl-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas.
    Wilson, WH
    Pittaluga, S
    O'Connor, P
    Hegde, U
    Drbohlav, N
    Janik, J
    Little, R
    Steinberg, S
    Cheson, B
    Staudt, L
    Raffeld, M
    Chabner, B
    Jaffe, ES
    BLOOD, 2001, 98 (11) : 343A - 343A
  • [4] LATE-ONSET NEUTROPENIA AFTER RITUXIMAB TREATMENT IN B-CELL LYMPHOMA: A SINGLE CENTRE EXPERIENCE
    Perrone, T.
    Gaudio, F.
    Scardino, S.
    Mastrorosa, A.
    Spina, A.
    Laddaga, F.
    Ingravallo, G.
    Cimmino, A.
    Specchia, G.
    HAEMATOLOGICA, 2012, 97 : 668 - 668
  • [5] Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.
    Lynch, Ryan C.
    Poh, Christina
    Ujjani, Chaitra Shankar
    Warren, Edus H.
    Smith, Stephen Douglas
    Shadman, Mazyar
    Morris, Karolyn
    Rasmussen, Heather
    Ottemiller, Susan
    Shelby, Megan
    Keo, Sarith
    Chabon, Jake J.
    Gooley, Ted
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Late-onset Neutropenia Following Rituximab Therapy as a Treatment of Diffuse Large B-cell Lymphoma: A Single Institution Study
    Kim, Minki
    Lee, Jin Kyung
    Hong, Young Jun
    Hong, Seek-Il
    Kang, Hye Jin
    Chang, Yoon Hwan
    KOREAN JOURNAL OF LABORATORY MEDICINE, 2010, 30 (06): : 575 - 579
  • [7] Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy
    Rozman, Samo
    Sonc, Monika
    Novakovic, Barbara Jezersek
    LEUKEMIA & LYMPHOMA, 2012, 53 (10) : 1945 - 1948
  • [8] Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients - Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage
    Lee, KW
    Kim, DY
    Yun, T
    Kim, DW
    Kim, TY
    Yoon, SS
    Heo, DS
    Bang, YJ
    Park, S
    Kim, BK
    Kim, NK
    CANCER, 2003, 98 (12) : 2651 - 2656
  • [9] Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy Following Doxorubicin-Based Chemotherapy for Primary Mediastinal Large B-Cell Lymphoma
    Li-ming, X.
    Ye-Xiong, L.
    Hui, F.
    Jing, J.
    Wei-Hu, W.
    Shu-Lian, W.
    Yue-Ping, L.
    Yong-Wen, S.
    Qing-Feng, L.
    Bo, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S554 - S554
  • [10] Dosimetric Evaluation and Treatment Outcome of Intensity Modulated Radiation Therapy After Doxorubicin-Based Chemotherapy for Primary Mediastinal Large B-Cell Lymphoma
    Xu, Li-Ming
    Li, Ye-Xiong
    Fang, Hui
    Jin, Jing
    Wang, Wei-Hu
    Wang, Shu-Lian
    Liu, Yue-Ping
    Song, Yong-Wen
    Liu, Qing-Feng
    Chen, Bo
    Qi, Shu-Nan
    Ren, Hua
    Dai, Jian-Rong
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (05): : 1289 - 1295
12